Spyre Therapeutics, Inc.

UBS Group AG SYRE

Report date

6/30/2023

Quarter

2023 Q2

Filed

8/11/2023

8,091

Value ($000)

Weight

0.0%

2019 Q4 - 2023 Q2 (14 filings)

Shares History

History scope: non-option holdings only (PUT/CALL rows excluded).

All 13F Holders	Filing date	Value ($000s)	% of Holdings	Shares	Reporting period
2023 Q2	8/11/2023	4	0.0%	8,091	6/30/2023
2023 Q1	5/12/2023	0	0.0%	7	3/31/2023
2022 Q4	2/8/2023	0	0.0%	8	12/31/2022
2022 Q2	8/10/2022	39	0.0%	76,806	6/30/2022
2022 Q1	5/16/2022	150	0.0%	65,276	3/31/2022
2021 Q4	2/14/2022	649	0.0%	136,636	12/31/2021
2021 Q3	11/15/2021	431	0.0%	54,220	9/30/2021
2021 Q2	8/13/2021	362	0.0%	52,077	6/30/2021
2021 Q1	5/12/2021	396	0.0%	49,973	3/31/2021
2020 Q4	2/11/2021	357	0.0%	45,360	12/31/2020
2020 Q3	11/12/2020	264	0.0%	37,285	9/30/2020
2020 Q2	7/31/2020	403	0.0%	43,569	6/30/2020
2020 Q1	5/1/2020	205	0.0%	44,036	3/31/2020
2019 Q4	2/14/2020	420	0.0%	55,003	12/31/2019